PSM Antibody (Y-PSMA2): sc-69665
- PSM Antibody (Y-PSMA2) is a mouse monoclonal IgG2b κ, cited in 4 publications, provided at 100 µg/ml
- raised against a crude membrane protein preparation from pooled prostate malignant carcinoma of human origin
- recommended for detection of PSM expressed LNCaP cell lines of human origin by WB, IP, IF and IHC(P)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for PSM Antibody (Y-PSMA2). This work is in progress.
QUICK LINKS
SEE ALSO...
PSM Antibody (Y-PSMA2) is a mouse monoclonal IgG2b light chain antibody that detects prostate-specific membrane antigen (PSM) in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-PSM antibody (Y-PSMA2) recognizes an integral membrane protein that plays a crucial role in prostate cancer progression, showing overexpression in malignant tumors while remaining largely absent in normal tissues, making PSM a valuable biomarker for diagnosis and treatment monitoring. PSM monoclonal antibody (Y-PSMA2) targets a protein characterized by a transmembrane domain, functioning effectively in cellular signaling and interaction, which is vital for tumor cell proliferation and metastasis. PSM (Y-PSMA2) antibody helps researchers study PSM′s role in tumor microenvironment interactions, enhancing its potential as a therapeutic target. The specificity of PSM for malignant prostate tissue, as opposed to benign conditions, underscores its importance in distinguishing between cancerous and non-cancerous states, thereby aiding in early detection and management of prostate cancer. PSM (Y-PSMA2) monoclonal antibody demonstrates robust performance across multiple applications, serving as an essential tool for researchers and clinicians focused on understanding and combating prostate cancer.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
PSM Antibody (Y-PSMA2) References:
- Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. | Rowe, SP., et al. 2016. J Nucl Med. 57: 90S-96S. PMID: 27694179
- Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. | Ahmadzadehfar, H. and Essler, M. 2020. Eur Urol. 77: 418-419. PMID: 30833140
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. | Paschalis, A., et al. 2019. Eur Urol. 76: 469-478. PMID: 31345636
- Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. | Sheehan, B., et al. 2022. Eur Urol Focus. 8: 1157-1168. PMID: 34167925
- Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications. | Tariq, A., et al. 2022. Eur Urol Focus. 8: 1256-1269. PMID: 34429271
- Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer. | Plichta, KA., et al. 2021. Int J Mol Sci. 22: PMID: 34829977
- Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers. | Meher, N., et al. 2022. ACS Appl Mater Interfaces. 14: 50569-50582. PMID: 36318757
- The Importance of Prostate-Specific Membrane Antigen Expression in Salivary Gland Tumors. | Sivrice, ME., et al. 2022. Turk Arch Otorhinolaryngol. 60: 206-211. PMID: 37456601
- Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostics for Prostate Cancer. | Solanki, K., et al. 2024. ACS Appl Bio Mater. 7: 5861-5884. PMID: 39192748
- Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. | Weiner, AB., et al. 2024. Eur Urol. 86: 579-587. PMID: 39294048
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PSM Antibody (Y-PSMA2) | sc-69665 | 100 µg/ml | $322.00 |